Validation and Application of an HPLC-DAD Method for Routine Therapeutic Drug Monitoring of Ceftobiprole | Zendy

Benjamin Lima | Zendy; Sandra Bodeau | Zendy; M.-C. Quinton | Zendy; Cyril Leven | Zendy; AnneSophie LemaireHurtel | Zendy; Youssef Bennis | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Validation and Application of an HPLC-DAD Method for Routine Therapeutic Drug Monitoring of Ceftobiprole

Author(s) -

Benjamin Lima,

Sandra Bodeau,

M.-C. Quinton,

Cyril Leven,

AnneSophie LemaireHurtel,

Youssef Bennis

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00515-19

Subject(s) - cephalosporin , pharmacokinetics , pharmacology , therapeutic drug monitoring , drug , neurotoxicity , antibacterial agent , broad spectrum , pneumonia , staphylococcus aureus , medicine , antibiotics , chemistry , microbiology and biotechnology , toxicity , combinatorial chemistry , biology , bacteria , genetics

Ceftobiprole is a fifth-generation cephalosporin approved for the treatment of pneumonia, with a broad antibacterial spectrum, including potent activity against methicillin-resistantStaphylococcus aureus . As for the other cephalosporins, high pharmacokinetic variability and concentration-dependent neurotoxicity are expected.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research